Randomized Controlled Trial for Paclitaxel-coated Balloon versus Plain Balloon Angioplasty in Dysfunctional Hemodialysis Vascular Access: 12-month Outcome from a Nonsponsored Trial

医学 气球 血管成形术 切割气球 血液透析 外科 随机对照试验 失调家庭 紫杉醇 血管通路 内科学 支架 化疗 再狭窄 精神科
作者
Skyi Yin-Chun Pang,Karen C.L. Au-Yeung,Grace Y.L. Liu,Ronald On‐Ho Tse,Donna Lai,Warren K W Leung,Ka Leung Mo,Chung Ngai Tang,Patricia Chun‐Ling Yih
出处
期刊:Annals of Vascular Surgery [Elsevier BV]
卷期号:72: 299-306 被引量:14
标识
DOI:10.1016/j.avsg.2020.10.005
摘要

Plain balloon angioplasty is regarded as the mainstay of treatment for failing vascular access with high success rate, but the poor treatment durability creates significant workload and increases patient morbidity. The study aims to compare target lesion primary patency rate at 12 months between paclitaxel-coated balloon (DCB) versus plain old balloon angioplasty (POBA) for treatment of dysfunctional vascular access.This nonsponsored-randomized trial enrolled 40 patients with dysfunctional dialysis access at a single center. Patients were randomized into In.Pact Admiral Paclitaxel DCB or POBA after lesion crossing regardless of lesion type. Patients are followed up under surveillance protocol. Patients, hemodialysis staff, and sonographer are blinded to the treatment arms. Twelve-month primary patency rate in both arms are evaluated.40 patients were recruited since June 2016 and were allocated to the DCB or POBA group. The mean age is 58 and 57 years with comparable demographic parameters. The locations of target lesion were comparable in both groups (juxta and arteriovenous anastomosis, cannulation site, and fistula/graft), with similar mean target lesion stenosis 69.8 +/- 15.8% for DCB and 69.5 +/- 13.6% for POBA (P = 0.95), and the lesion length for DCB is 45.8 +/- 38.4 mm and 50.2 +/- 33.5 mm for POBA (P = 0.70). Patients in DCB performed significantly better in terms of primary patency at 6 months 85% versus 55% (P = 0.007). The superiority in primary patency in DCB group exists at 12 months 65% versus 30% (P = 0.007).Paclitaxel balloon angioplasty approach provides significant better primary patency in dysfunctional arteriovenous access at 12 months in our nonsponsored-randomized trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭栋完成签到,获得积分10
刚刚
Lu发布了新的文献求助10
刚刚
刚刚
5秒前
桔子完成签到,获得积分10
7秒前
二般人完成签到 ,获得积分10
12秒前
忐忑的阑香完成签到,获得积分10
13秒前
13秒前
罗晓倩完成签到,获得积分10
13秒前
ShiyuZuo完成签到,获得积分10
14秒前
诚心千筹发布了新的文献求助10
17秒前
17秒前
YamDaamCaa应助shawn采纳,获得100
20秒前
桃子完成签到,获得积分20
20秒前
Rondab应助大观天下采纳,获得30
21秒前
DijiaXu应助爱科研采纳,获得10
24秒前
水中鱼完成签到,获得积分10
24秒前
共享精神应助无情的匪采纳,获得10
24秒前
科目三应助yoyo采纳,获得10
24秒前
25秒前
前隆是狗完成签到,获得积分10
25秒前
yyyyyyy111发布了新的文献求助10
28秒前
SYLH应助淅淅12345采纳,获得10
29秒前
31秒前
YWang发布了新的文献求助10
32秒前
李健的小迷弟应助hh采纳,获得10
33秒前
35秒前
Orange应助莉丽采纳,获得10
35秒前
36秒前
juwish完成签到,获得积分10
37秒前
cst发布了新的文献求助10
37秒前
量子星尘发布了新的文献求助10
37秒前
Fengliguantou发布了新的文献求助10
38秒前
38秒前
脑洞疼应助zriverm采纳,获得10
39秒前
林宝雯发布了新的文献求助10
40秒前
cccyq完成签到,获得积分10
41秒前
42秒前
诚心千筹完成签到,获得积分10
43秒前
44秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073